NCT01421719View on ClinicalTrials.gov

Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

July 31, 2011

Conditions
Parkinson's DiseaseNeurogenic BladderUrinary IncontinenceClostridium Botulinum Toxin Adverse Reaction
Interventions
DRUG

Cystoscopic injection of Botox into the urinary bladder

100 U of Botox A injected transurethrally into the urinary bladder muscle and submucosa.

Trial Locations (1)

94305

Stanford University Hospital and Clinics, Stanford

Sponsors

Collaborators (1)

Allergan
All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Stanford University

OTHER